


November 2025

2025 Sustainability Report





Contents

Section I.	About bit.bio
Section II.	Message from our CEO, Board and Sustainability Leaders
Section III.	Our UN Sustainable Development Goals
Section IV.	Looking Forward
Section V.	Appendix

Section I. About bit.bio

bit.bio is a synthetic biology company revolutionising access to human cells, with the goal of accelerating innovation in biomedical research and enabling next-generation therapies for good health and well-being. Built on Nobel Prize-winning discoveries in gene regulation and cell identity, our proprietary *opti-ox*™* technology allows for the precise and scalable conversion of induced pluripotent stem cells (iPSCs) into any human cell type in a single step. This process delivers consistent, highly pure cells within days and at industrial scale.

Our platform underpins key product lines for research and drug discovery. The ioCells portfolio continues to expand and includes ioWild Type Cells, ioDisease Model Cells, and CRISPR-Ready ioCells—each designed to meet the growing demand for reliable, high-quality human cells in pharmaceutical and biotech R&D.

We are committed to advancing the global adoption of New Approach Methodologies (NAMs). By delivering a reliable source of consistent human cells, we enable the scientific community to transition toward more predictive, human-relevant systems and reduce reliance on animal models.

Our Values



- **Purposeful:** We are guided by our purpose, aligned to that of our namesake: coding biology for the benefit of humanity. We overcome our daily challenges by putting purpose first.
- **Ambitious:** We are driven and ambitious in our creation of products that have value to society. Together we will change the world.
- **Collaborative and Trustworthy:** Our purpose and mission hinge on leveraging our combined knowledge and skills. We value diversity and the power of collaboration.
- **Empirical:** We embrace the scientific method and put facts above opinions. In the absence of data, we generate it. We see the world as full of opportunities and approach it with a mindset of abundance.

* For information on bit.bio's trademarks, visit www.bit.bio/trademarks

Section II. Message from Our CEO, Board and Sustainability Leaders



Przemek Obloj
CEO



Mark Kotter
Founder



Prof. Marie-Claire Cordonier Segger
Chair – Ethics & Sustainability Board



Yihan Pei
Director of Business Finance & Strategy

As we reflect on 2024, we are pleased to share the progress our organisation has made in advancing our Corporate Sustainability Strategy. These accomplishments are the result of the dedication of our employees and the integration of sustainability into the very fabric of our business structure, operations, and values.

We continue to recognise the climate crisis as one of the most pressing challenges of our time and remain steadfast in our commitment to addressing it. As a participant in the UN Race to Zero campaign, we have accelerated the implementation of initiatives that move us closer to our net-zero ambitions, well ahead of the global 2050 target. In 2024, improvements across production, packaging, and distribution contributed to our ongoing efforts to reduce environmental impact while delivering value to our stakeholders, leading to a Platinum Award from Green Impact.


Our view of sustainability extends beyond the environment. Guided by the UN Sustainable Development Goals, we are dedicated to innovating for better health through the advancement of New Approach Methodologies. This focus allows us to support the transition to human-relevant systems and build a future that is both more ethical and sustainable.

Central to this progress is our culture, which empowers employees to take ownership of change and fosters a collective sense of accountability. This values-based approach strengthens engagement, drives continuous improvement, and ensures that sustainability is not a discrete initiative, but a core element of our long-term strategy and operations.

This report marks the release of our second Annual Sustainability Report, covering 2024. We aim to provide a transparent account of the advancements we have achieved and the challenges we must continue to address. Accountability and transparency remain guiding principles of our approach, as we believe that companies that consistently align growth with societal value will secure enduring competitive advantage. Our commitment is to deliver superior growth by creating long-term value for all stakeholders—customers, employees, partners, investors, and the communities we serve.

Together with our stakeholders, we are advancing toward a healthier, more sustainable future—one cell at a time.

Section III. Our UN Sustainable Development Goals (SDGs)



At bit.bio, we believe in building a sustainable business from the ground up as part of our responsibility to protect the planet for future generations. For this commitment, we have aligned with the SDGs, focusing on three primary goals and seven supporting goals. These priorities shape our Corporate Sustainability Strategy and the work of our committee, guiding both our day-to-day operations and long-term vision.

Each SDG includes specific targets developed by the UN. We have identified the applicable targets for each bit.bio SDG, with progress towards each target measured through specific key performance indicators, and lead employees appointed to oversee advancement towards our goals.

Our commitment to sustainability reflects the core values of our employees, shareholders, and broader stakeholder community. At bit.bio, our engagement with the SDGs is not peripheral, it is central to our vision for the future. This belief drives our decision to voluntarily publish our Sustainability Report, demonstrating transparency in our progress.

Our Corporate Sustainability Strategy

Our sustainability strategy is essential for aligning the company’s operations with long-term environmental, social, and economic goals. It provides a structured approach to identifying priorities, setting measurable targets, and integrating sustainability into core business functions. Beyond mitigating risks and ensuring regulatory compliance, a well-defined strategy helps drive innovation, enhance stakeholder trust, and create long-term value.


We are leveraging our platform technologies to tackle the world’s biggest social and environmental challenges, particularly by driving innovation in NAMs to create a more ethical and predictive research landscape. We seek to lead on social responsibility and sustainability as we empower researchers to develop the next generation of cures.

Corporate Sustainability Strategy			
Corporate Sustainability Commitments	Customers / patients	Team	Society & environment
Mobilise expertise for health, life, and innovation	Democratise access to human cells for research, drug discovery and therapeutics	Promote a diverse and inclusive workplace to realise the full potential of our team	Deliver on our responsibilities towards others, our societies and planet
Steward ethical and sustainable enterprise	Maintain high standards of ethics, quality and safety	Protect human rights and workplace safety	Maintain carbon-negative footprint and prioritise sustainability across our operations
Contribute to community and world	Harness the power of our technology to do good	Enable team to innovate to make a better world	Lead in research, education and sustainability, locally and globally

bit.bio Green Team

The bit.bio Green Team is a group of volunteers from across the company that meets regularly to advance initiatives to improve sustainable practices within the company. They also drive organisational engagement in our sustainability programmes, including the Green Impact and UN Race to Zero.

They are constantly evaluating our office and lab processes to enhance sustainability, arranging events, and participating in Babraham Campus sustainability activities.



Won the **Bronze Award** 2022



Won the **Gold Award** 2023



Won the **Platinum Award** 2024

“I’m incredibly proud that bit.bio has earned Green Impact’s Platinum award in 2024. This achievement reflects not just our commitment to sustainability, but the collective effort of our whole team to make a real difference for people and the planet.”



Megan Doe
VP, Business Finance & Strategy



bit.bio joined the world’s efforts against climate change by signing on to the United Nations Race to Zero. We are committed to achieving net zero and beyond, ahead of the 2050 deadline. More specifically, we aim to halve our greenhouse gas emissions by 2030 and achieve net zero before 2040. To accomplish this, we are continuously assessing and enhancing our operations, including:

- Measuring and reporting our progress on a yearly basis
- Implementing decarbonisation strategies in line with the Paris Agreement through interrogating each step of operations to guarantee energy and resource efficiency
- Neutralising any remaining emissions with additional, quantifiable, real, permanent, and socially beneficial offsets

In 2024:

- Carbon emissions from travel decreased by 7.3% compared to 2023
- Electricity use decreased 5.8% compared to 2023 despite workforce growth
- Gas usage decreased from 11.5 tonnes to 1.1 tonnes

3 GOOD HEALTH AND WELL-BEING



- Develop ioCells that facilitate drug discovery efforts in relevant diseases
- Advance NAMs and provide human-relevant models for more predictive research
- Enable the development of cell therapies to treat patients with relevant diseases

At bit.bio, our ambition is clear: to build a scalable technology platform that delivers consistent, high-quality batches of every disease-relevant human cell type. By doing so, we are opening access to human cells for research, drug discovery, and cell therapy development—helping to democratise innovation in healthcare.



Mark Kotter
Founder

“From founding to start-up to scale-up, bit.bio is redefining what’s possible with human cells. bit.bio’s leadership in scalable, consistent iPSC-derived cell manufacturing is underpinned by our strong intellectual property portfolio and pioneering opti-ox technology. This combination positions us as the global market leader and accelerates the development of next-generation cell therapies and research tools. It is an incredible adventure, and I am humbled and honoured to be part of this purpose-led company that is transforming our field, and our world.”

Through ioCells, including ioWild Types, ioDisease Models, and CRISPR-Ready ioCells, we are providing researchers and drug developers with high-quality, reliable tools that enhance therapeutic discovery and development.

In 2024:

- **41 ioCells products related to non-communicable diseases**
- **4 ioCells products relevant to children**
- **Number of academic institutions using ioCells products increased by 12x over 5 years**



Thomas Moreau
VP, Cell Programming
Research & Innovation

“At bit.bio, we are supporting advancements in cell programming and synthetic biology to provide uniquely precise and consistent human cells with applications in research, drug discovery and cell therapy. This field is not only at the forefront of biomedical innovation but also addressing the industries ongoing ethical challenges.”





- Establish scientific infrastructure for bit.bio to support human well-being
- Lead scientific research, encouraging innovation and increasing research and development workers in UK and countries of operation

Innovation fuels progress, shapes our response to challenges, and ensures we remain at the forefront of biotechnology. Beyond scientific excellence, it requires the courage to experiment, adapt, and evolve.

We continually refine our processes to enhance efficiency, remove bottlenecks, and accelerate the development of scalable, high-quality cell types for biomedical research and therapeutic applications. Investing in innovation and infrastructure is fundamental to our mission of building a healthier, more sustainable future. By engineering and promoting advanced cell models, we equip our customers with the innovative tools necessary to drive subsequent discoveries in their fields.

In 2024:

- **We spent >\$35 million on Research and Development**
- **We had 110 employees that were involved in Research and Development activities**
- **73% of our staff were scientific workers**

“Our company is making a global difference, and it is inspiring to contribute. bit.bio cells are being used at the forefront of innovation. One example is how Cortical Labs, an Australian biotech start-up, has been experimenting with our cells to fuel computers. By integrating the cells into microchips, they essentially act as the central processing unit for a computer. Although still in the experimental phases, if successful this fascinating technology would significantly reduce the amount of energy and water consumed for current AI advances.”



Emma Pepperell
VP, Commercial





- Reduce emissions to zero in keeping with the UN Race to Zero campaign
- Reduce waste and increase recycling

While striving to maximise our impact on human health and minimise impact on animal health through advancing NAMs and enabling the 3Rs (Replacement, Reduction, Refinement), we are equally committed to minimising our impact on the environment and ensuring the fair and equitable use of its resources.



Selja Salic
VP, R&D
bit.bio Vienna

“Younger colleagues are particularly attentive to the SDGs and sustainability issues. During recruitment, we frequently receive questions about animal use and other ethical concerns. Our commitment to enabling the Life Science ecosystem reduce animal testing aligns with these values and makes bit.bio an attractive workplace for the next generation.”

bit.bio's work aligns with international agreements to ensure the just and equitable sharing of benefits arising from the utilisation of genetic information. We will measure our progress through our ability to democratise ioCells and cell therapies at reduced costs. We are consciously decoupling our growth from our ecological impact.

In 2024:

- **Introduced new travel policy to reduce unessential travel**
- **100% of our cafeteria menu was vegetarian**
- **Released our first Annual Sustainability Report**

“At bit.bio, we believe that integrating sustainability into our operations both upholds our core values and creates tangible business value. For instance, in 2024 we introduced a travel policy that contributes to our climate change pledge by reducing GHG emissions. We have seen growing investor interest in environmental responsibility, and as the company scales, we are ensuring that we monitor our environmental impact and work to minimise it.”



Sam Jones
Director, Finance



Secondary Targets

2 ZERO HUNGER



bit.bio technology provides the opportunity to satisfy the world's appetite for meat without harming people, animals, or the planet. Lab-grown meat negates the ethical challenges posed by meat consumption, reduces the negative land impacts caused by animal production, and improves population access to nutritious protein sources.

Meatable, a licensee of bit.bio's technology to make lab-grown meat, opened a new pilot facility in 2024. As the demand for meat is set to grow from 350 billion kg annually to more than 450 billion kg by 2050, cultivated meat could have a significant impact in reducing the meat industry's impact while helping to feed the world's growing population.

Meatable in 2024:

- **opti-ox named one on TIME Magazine's Best Inventions 2024**
- **Began a partnership with Desmos Capital Partners**
- **Received investment from Thailand's Betagro**



4 QUALITY EDUCATION



bit.bio is committed to supporting the next generation of innovators. We emphasise the importance of professional and personal development for young people and seek to provide opportunities to as many talented young people as possible.

In 2024:

- **Internships offered doubled**
- **New training programme launched**
- **Over 50 training modules available on Viva Platform**

“Interning at bit.bio gave me hands-on experience and encouraged me to pursue multiple degrees and a career in the life sciences. I feel proud to have contributed to bit.bio's commitment to ethics and sustainability; it's always exciting to see how much has changed each time I come back!”

Thalia Edwards



5 GENDER EQUALITY



bit.bio is passionate about ensuring women's full participation in our synthetic biology revolution. In 2024 we maintained our commitment of equal distribution of employees and leadership opportunities by gender and ensuring gender pay parity.

In 2024:

- **57% of employees were women**
- **50/50 distribution of promotions by gender**
- **Leadership team maintained gender parity**

We also have policies containing equal opportunities statements and our hiring policy asks for potential hires to notify us of any adjustments needed. We have embedded these values into our **Dignity at Work Policy**.

In addition to promoting gender equality in our workforce, bit.bio is expanding its cell type portfolio to account for biological variation in diseases. For example, bit.bio markets both female and male donor-derived ioMicroglia, allowing scientists to conduct more customised research, with more along the way.

8 DECENT WORK AND ECONOMIC GROWTH



- Undertake high-value added and innovative cell engineering

Real economic growth depends on an informed, trained, and engaged workforce and a commitment to sustainability. We have the capacity to continue shaping the future of the synthetic biology industry so that its medical and economy benefits can be shared as widely as possible.

“At bit.bio, we can scale manufacturing output two- to threefold, all with capacity fully in-house. This allows us to expand rapidly without increasing our footprint, while ensuring the highest levels of consistency, quality and cost-efficiency. It's exciting and inspiring to be at the forefront of such crucial developments in our field.”



Orlaith Greenan
VP, Operations

In 2024:

- **Approximately 185 employees**
- **59 corporate policies on Decent Work**
- **47% revenue growth in 2024**

12 RESPONSIBLE CONSUMPTION AND PRODUCTION



- Adhere to guidelines for chemical use and removal

As producers, we are committed to maximising safety and minimising impact through developing detailed chemical waste policies.

In 2024:

- **Launched weekly flash report notifying staff of Risk and COSHH assessments**
- **71 risk assessments conducted between June 2024-2025**
- **9 active waste recycling streams**

As consumers, waste minimisation is central to our sustainability goals. bit.bio places an emphasis on food waste reduction in our café and recycling improvements in our office and lab spaces.

“bit.bio is constantly pushing the envelope and aiming higher for success. We've proven that we can significantly reduce production time in our operations. From a sustainability point of view, that means we're using less energy, less incubators and less plastic.”



Karl Firth
Senior Director,
Manufacturing

13 CLIMATE ACTION



- Align to established climate campaigns and track / publish annual sustainability report

Building a low-carbon future is embedded across our operations, with our Race to Zero pledge serving as a cornerstone of our corporate strategy. Each year, we share progress toward our goal of reaching net zero by 2040. To support this ambition, we foster a culture of sustainability by enabling employees to turn their environmental commitment into action.

“This year we've trialed lowering freezer temperatures from -80C to -70C [to save energy]. It's still a work in progress but we have started that conversation.”



Laraine Crossland
Lab and Infrastructure
Operations Manager

In 2024:

- **Achieved 504 points in Green Impact, over 100 points more than the threshold for Platinum award**
- **Held a charity event raising money to purchase solar panels for a local primary school**

16 PEACE, JUSTICE AND STRONG INSTITUTIONS



- Develop, implement and orient employees on Ethics Code and policies

Our Code of Business Conduct and Ethics, together with our Science, Research, and Conduct Ethics Policy, form the foundation of our workplace culture, supported by comprehensive policies on anti-corruption, dignity at work, whistleblowing, and career development.

In 2024:

- **97% Codes of Ethics training completion**

“At bit.bio, sustainability and ethics are not mere marketing labels, nor are they add-ons. The company is deeply committed to ensuring that breakthroughs delivered in science are matched with rigorous ethical standards and world-leading sustainability practices. For instance, their technology has the chance to enable a seismic shift in biomedical research – away from poorly predictive and outdated animal testing across the board.”



Jeff Skopek
Board Member
Independent ethics and sustainability board
University of Cambridge

Section IV. Looking Forward

A message from the CEO and ESB Chair



Przemek Obloj
CEO



**Prof. Marie-Claire
Cordonier Segger**
Chair – Ethics &
Sustainability
Board

Our journey is defined by a commitment to becoming a cornerstone of therapeutic discovery, empowering researchers to build the future of medicine. Today, we are emerging as a global leader in creating and manufacturing human cells with unmatched precision and scale, driving step-change improvements in drug discovery and research. We are on a path to making a meaningful difference for millions of researchers and patients, while building a highly valuable business in the process.


At bit.bio, we see sustainability as a journey of accountability and progress. Each year, we measure and report on our impact against the SDGs that guide our mission. The 2024 Sustainability Report marks our second annual milestone, and we remain committed to building on this foundation, sharing our achievements and amplifying the positive change we strive to deliver for health, innovation and a sustainable future.

The momentum behind our sustainability commitments is powered by a team that brings passion, diversity, expertise, and purpose to everything they do. bit.bio has been fortunate to attract individuals who come here with a dual mission: to grow their careers while helping to make the world a better place. I am deeply grateful of the values and dedication our team demonstrates every day.

Looking ahead to 2025 and beyond, we envision a future where science and sustainability work hand in hand to improve human health and safeguard the planet. Our commitment extends past meeting quarterly targets, we aim to lead with purpose. Together, we will shape a world that is cleaner, greener, and more equitable for generations to come.



Section V. Appendix



2024 Carbon Emissions


Business Travel

CO₂ emissions

We track emissions from our business travel (flights and hotels) using our travel platform.

Total employee travel generated **450.9 tonnes of CO₂ emissions in 2024**

bit.bio CO₂ emissions over the past 3 years due to travel



Waste

KG of waste

We generated approximately **21,641.4 kgs of lab waste**

This waste is also a significant area for potential cost savings. bit.bio disposes of 408 lab waste bins per month equating to over £9,000.

Purchase	60L Clinical Bin £12.10
Disposal	One 4.43kg bin £10.37

= **£22.47**
Per bin

Data on total waste usage was not available this reporting period.

Electricity & Gas

kWh

We track emissions from our own operations and eliminate them in due course. Our ambition is to eliminate all of our emissions.

Our electricity and gas consumption is 100% REGO renewable certified.

Key KPIs	2022	2023	2024
Total Electricity (kWh)	1,613,874	645,814	608,763
Total Gas (m3)	-	11,518	1,075
Carbon Emissions from energy (tonnes)	244.5	147.42	170.11

Electricity and gas usage was lower in 2024 compared with 2023, increased overall emissions were due to a change in calculation methodology*.

* Calculated using Carbon Footprint Calculator - Sustrax

Carbon Offsets

In addition to local and internal mitigation and resilience efforts that will help us to go carbon negative over time, bit.bio is investing in high impact and value international carbon reduction projects. Our chosen partners, The International Small Group and Tree Planting Program (TIST), Gold Standard, and Carbon Footprint, were selected by the staff together in a vote.

- Remaining emissions are offset externally, via strategically engaging with three offset beneficiaries outlined below. These partners and their respective weighting were selected by employees.
- We will complete these offsets by the end of 2025.



External offset partner	External offset amount (Ton)
TIST (10% weight)	63
Gold Standard (45% weight)	279
Carbon Footprint (45% weight)	279
Total	621

2040 roadmap and emission reduction initiatives

As we progress in our commitment to reduce carbon emissions, we are continuing to undertake initiatives to limit our carbon footprint. Select examples include commuting, office and laboratory.

In recognition of these efforts, bit.bio received the Green Impact Platinum award in 2024.

Commuting

- Support hybrid working
- Promote commuting methods with lesser carbon footprints (e.g. electric vehicle scheme, subsidised bus pass, car sharing, cycle to work scheme)

Office

- Choose sustainable suppliers for office supplies
- Offer subsidised 100% vegetarian menu in café
- Implement new recycling schemes (e.g. crisp packages, batteries)

Laboratory

- Choose sustainable suppliers for consumables and reagents
- Implement glove and plastics recycling to avoid incineration
- Reduce carbon impact of shipping materials

Sample of KPIs tracked against SDGs committed to by bit.bio

bit.bio's key SDGs Primary Objectives		bit.bio's Contributions towards SDGs	KPI(s)	Timeframe
3 Good Health & Well-being				
3.2	By 2030, end preventable deaths of newborns and children under 5 years of age, with all countries aiming to reduce neonatal mortality (at least as low as 12 per 1,000 live births) and under-5 mortality to at least as low as 25 per 1,000 live births	Develop cell therapies to treat patients with relevant diseases	Number of cell therapy programs that address relevant diseases, of which a number are particularly relevant to children	Longer term
			Number of patients treated with our cell therapy products, of which a number are children under 5	Longer term
		Develop to Cells (wild types and disease models) that facilitate drug discovery efforts in relevant diseases	Number of marketed to Cells products that relate to relevant diseases, of which a number are relevant to children	Longer term
			Number of customers using to Cells to research relevant diseases, of which a number are relevant to children	Longer term
3.4	By 2030, reduce by one third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-being	Develop cell therapies to treat patients with relevant diseases	Number of cell therapy programs that address relevant diseases	Longer term
			Number of patients treated with our cell therapy products	Longer term
		Develop to Cells (wild types and disease models) that facilitate drug discovery efforts in relevant diseases	Number of marketed to Cells products that relate to relevant diseases	Longer term
			Number of customers using to Cells to research relevant diseases	Longer term
3.5	Strengthen the prevention and treatment of substance abuse, including narcotic drug abuse and harmful use of alcohol	Develop cell therapies to treat patients with relevant diseases (e.g., liver failure, cirrhosis)	Number of cell therapy programs that address relevant diseases	Longer term
			Number of patients treated with our cell therapy products	Longer term
3.8	Achieve universal health coverage, including financial risk protection, access to quality essential health-care services and access to safe, effective, quality and affordable essential medicines and vaccines for all	Develop to Cells that facilitate drug discovery efforts to relevant diseases	Number of marketed to Cells products related to relevant diseases	Longer term
			Number of customers using to Cells to research relevant diseases	Longer term
3.b	Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all	Develop cell therapies to treat patients with relevant diseases	Cell therapy COGS	Longer term
			Cell therapy pricing and reimbursement strategy	Longer term
		Develop cell therapies at reduced cost (1-2 orders of magnitude lower than current cell therapies) to facilitate lower prices and democratisation of access	Number of cell therapy programs that address relevant diseases	Longer term
			Number of patients treated with our cell therapy products	Longer term
			Cell therapy COGS	Longer term
			Cell therapy pricing and reimbursement strategy	Longer term
			Number of marketed to Cells products that relate to relevant diseases	Longer term
			Number of customers using to Cells to research relevant diseases	Longer term
9 Industry, Innovation and Infrastructure	Develop quality, reliable, sustainable and resilient infrastructure, including regional and transborder infrastructure, to support economic development and human well-being, with a focus on affordable and equitable access for all	Develop cell therapies at reduced cost (1-2 orders of magnitude lower than current cell therapies) to facilitate lower prices and democratisation of access	Number of research partnerships with other roles	Longer term
			Number of peer-reviewed/published studies mentioning our research	Longer term
			Number of PhD students funded	Relevant term
9.1	Develop quality, reliable, sustainable and resilient infrastructure, including regional and transborder infrastructure, to support economic development and human well-being, with a focus on affordable and equitable access for all	Establish scientific infrastructure for bit.bio to support human well-being	Number of lab and other work stations	Relevant term
			Discovery Pipeline Development (increase number of perturbations)	Relevant term
9.4	By 2030, upgrade infrastructure and retrofit industries to make them sustainable, with increased resource-use efficiency and greater adoption of clean and environmentally sound technologies and industrial processes, with all countries taking action in accordance with their respective capabilities	Implement Green Impact policies and practices at bit.bio including resource-use efficiency and clean and environmentally sound technologies and processes	Green Impact Award programmes and progress	Relevant term
9.5	Enhance scientific research, upgrade the technological capabilities of industrial sectors in all countries, in particular developing countries, including, by 2030, encouraging innovation and substantially increasing the number of research and development workers per 1 million people and public and private research and development spending	Lead scientific research, encouraging innovation and increasing research and development workers in UK and countries of operation	Number of R&D employees	Relevant term
			R&D spend	Relevant term
			Number of cell type programs at each stage in the clinical pipeline	Relevant term
15 Life on Land				
15.1*	By 2020, ensure the conservation, restoration and sustainable use of terrestrial and inland freshwater ecosystems and their services, in particular forests, wetlands, mountains and drylands, in line with obligations under international agreements	Support the development of bit.bio government via Mivabite to 1) mitigate climate issues and 2) reduce negative land impacts related to animal production, and to 3) improve population access to nutritious protein sources	Kilograms of bit.bio meat sold by Mivabite	Longer term
		Reduce carbon emissions to align with the UN Race to Zero campaign - internal and external efforts	* Publish annual carbon report, documenting internal and external (scope 1 & 2) efforts to take emissions to zero	Relevant term
15.5	Take urgent and significant action to reduce the degradation of natural habitats, halt the loss of biodiversity and, by 2020, protect and prevent the extinction of threatened species	Purchase from sustainable suppliers	Percent of purchases that are from identified sustainable suppliers	Relevant term
		Reduce waste and increase recycling (e.g., plastic, bit.bio waste)	Kilograms of collected waste	Relevant term
		Offer 100% vegetarian menu in canteen	Number of recycling streams	Relevant term
			Percent of menu that is vegetarian	Relevant term
15.6	Promote fair and equitable sharing of the benefits arising from the utilization of genetic resources and promote appropriate access to such resources, as internationally agreed	Support the development of bit.bio government via Mivabite to reduce the land impact of animal production	Kilograms of bit.bio meat sold by Mivabite	Longer term
		Develop cell therapies at reduced cost to facilitate lower prices and democratisation of access	Cell therapy COGS	Longer term
			Cell therapy pricing and reimbursement strategy	Longer term
			Number of marketed to Cells products	Relevant term
15.a	Mobilize and significantly increase financial resources from all sources to conserve and sustainably use biodiversity and ecosystems	Partner with other companies / foundations to develop cell therapies and vaccines for various diseases with animal models	Number of customers using to Cells	Relevant term
			Number of partnerships	Relevant term
15.a	Mobilize and significantly increase financial resources from all sources to conserve and sustainably use biodiversity and ecosystems	Reduce carbon emissions to align with the UN Race to Zero campaign - internal and external efforts	* Publish annual carbon report, documenting internal and external (scope 1 & 2) efforts to take emissions to zero	Relevant term
		Purchase from sustainable suppliers	Percent of purchases that are from identified sustainable suppliers	Relevant term
		Offer 100% vegetarian menu in canteen	Percent of menu that is vegetarian	Relevant term

*In collaboration with Mivabite